Close Menu

TessArae

While ethnicity-based screening remains the consensus approach for identifying disease-causing mutations, the American population is becoming increasingly admixed, meaning that genetic laboratories often have to run multiple panels on the same individual.

NEW YORK (GenomeWeb News) – TessArae and Kindstar Global today announced a collaboration to develop genetic tests for the Chinese population.

Galil Genetic Analysis recently began offering its OncoGenetics RDMGGA 1.0 Re-sequencing Chip as a service to its customers in Israel, according to the company's CEO.

IP Roundup: Jun 14, 2011

Premium

Callida Genomics, Illumina, SRU Biosystems, George Mason University, Receptors, TessArae, Affymetrix

Thomas Richards, Ronald Davis

The partnership is one of several for TessArae, which has traditionally served the infectious disease-testing market, but has recently begun offering services to genetic disease-testing firms.

The vote of confidence is a stepping stone for the company to seek 510(k) approval for an H1N1 test on its platform; to tackle the point-of-care diagnostic market; and to further develop tests for other infectious diseases.

By obtaining emergency use authorization from the FDA, Potomac Falls, Va.-based TessArae becomes the first array firm to have received an EUA to sell chips for the monitoring and early diagnosis of the H1N1 influenza A virus.

The assay was developed through Affymetrix's MyGeneChip Custom Array Program. It is the latest in a series of molecular diagnostic products to get an FDA EUA.

For TessArae, which specializes in developing pathogen-detection arrays, the deal with GeneDx is the first of its kind. The company said this week that it intends to pursue more opportunities in the genetic disease-testing arena.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.